Publication details

Význam nádorového supresoru p53 u chronické lymfocytární leukemie.

Title in English The role of TP53 gene in chronic lymphocytic leukemia.
Authors

MALČÍKOVÁ Jitka POSPÍŠILOVÁ Šárka MAYER Jiří TRBUŠEK Martin

Year of publication 2010
Type Article in Periodical
Magazine / Source Transfuze a hematologie dnes
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords ATM; chronic lymphocytic leukemia; prognostic factors; TP53
Description The p53 protein is a key cell cycle regulator that protects cells from genotoxic and oncogenic stress and plays a crucial role in preventing cancer development. Even a loss of one allele predisposes the cell to malignant transformation and p53 proteins with missense mutations can adopt novel oncogenic properties. In chronic lymphocytic leukemia (CLL)the TP53 abnormalities occur with a relatively low frequency (10-15%), however they are of a high prognostic impact. Patients with p53defects suffer from aggressive disease and are often resistant to standard chemotherapy. Novel therapeutic approaches acting independently on the p53 pathway are recently available. The TP53 gene is usually impaired by deletion of one and mutation of the other allele, however, relatively large cohort of patients bears only mutations and separate mutations have negative impact on patients survival that is not significantly different from patients with complete p53 inactivation. P53 abnormalities can occur during the course of the disease and therapy plays an important role in their selection.

You are running an old browser version. We recommend updating your browser to its latest version.

More info